Helus Pharma Inc. (HELP)

$7.73 -1.24 (-13.82%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 864,772
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterate...

Industry: Biotechnology
Sector: Healthcare
Phone: 908-764-8385
Website: cybin.com
Address:
100 King Street West, Suite 5600, Toronto, Canada
RuddyRolls
RuddyRolls Jun. 8 at 10:31 PM
$HELP cheerful morning here I see
0 · Reply
Alex1710
Alex1710 Jun. 8 at 10:17 PM
$HELP I don't know but it looks like an all time low. Could not get worst. There is defenetly something wrong with this company. Hiring a CEO and making him leave 6 weeks after shows a real management deficiency. CMPS will take the lead, being the first with a new drug gives a major advantage unless your drug is better. Glad I have a small position.
0 · Reply
kev90123
kev90123 Jun. 8 at 8:03 PM
$HELP The "Leadership" team is going on vactions with your money every weekend. Big summer planned!!! @HelusPharmaIR
0 · Reply
matrixtrade123
matrixtrade123 Jun. 8 at 5:56 PM
$ATAI dang Dogs $HELP is making ALL TIME LOWS left that Shit Show years ago when Doug was the Ringleader __ Top Gun Cannabis Stocks finally looking good !
0 · Reply
Buckwacker
Buckwacker Jun. 8 at 5:02 PM
$HELP I’ve averaged down when it fell into the fives, my balls ain’t big enough Man I’m at the point do I sell it take the loss on the chin and try and put the change into quantum or space and rebuild the 💰 Four-five years festering away
0 · Reply
grumpygoose
grumpygoose Jun. 8 at 4:39 PM
$HELP "Sorry kids, there won't be any family vacation this year. Your father invested in HHEELLLPPPPPPPPPP"
1 · Reply
kev90123
kev90123 Jun. 8 at 4:02 PM
$HELP @HelusPharmaIR
0 · Reply
brunoq14
brunoq14 Jun. 8 at 3:43 PM
$HELP Get AI to explain to you what "adjunctive" and "deuteration" mean. Then you'll have a pretty good idea of the advantages of HLP003.
2 · Reply
FruitOs
FruitOs Jun. 8 at 2:26 PM
$HELP we all hate you 😊
0 · Reply
FruitOs
FruitOs Jun. 8 at 2:01 PM
$HELP criminals
0 · Reply
Latest News on HELP
Cybin Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 2:35 PM EDT - 4 days ago

Cybin Transcript: Jefferies Global Healthcare Conference 2026

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Jun 1, 2026, 7:30 AM EDT - 7 days ago

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 30, 2026, 7:17 PM EDT - 5 weeks ago

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Apr 30, 2026, 7:30 AM EDT - 5 weeks ago

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 28, 2026, 7:30 AM EDT - 5 weeks ago

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

Apr 23, 2026, 7:30 AM EDT - 6 weeks ago

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

How Trump's psychedelics executive order could unlock stalled cannabis reform

Apr 20, 2026, 2:05 PM EDT - 7 weeks ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS DFTX GHRS

Helus ‘welcomes’ Executive Order for accelerating psychedelic research

2026-04-20T14:47:00.000Z - 7 weeks ago

Helus ‘welcomes’ Executive Order for accelerating psychedelic research

Helus Pharma announces Cola is stepping down as CEO, appoints So as Interim CEO

2026-04-20T12:41:24.000Z - 7 weeks ago

Helus Pharma announces Cola is stepping down as CEO, appoints So as Interim CEO

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Apr 20, 2026, 8:15 AM EDT - 7 weeks ago

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

Apr 20, 2026, 6:43 AM EDT - 7 weeks ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX ENVB GHRS

Helus Pharma appoints Kramer as Senior Vice President, Medical Affairs

2026-04-16T11:38:27.000Z - 7 weeks ago

Helus Pharma appoints Kramer as Senior Vice President, Medical Affairs

BMY

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Apr 16, 2026, 7:30 AM EDT - 7 weeks ago

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Helus Pharma initiated with a Buy at TD Cowen

2026-04-13T09:50:28.000Z - 2 months ago

Helus Pharma initiated with a Buy at TD Cowen

Cybin Slides: Corporate presentation

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Cybin Slides: Corporate presentation

Helus Pharma appoints Conwell as Chief People Officer

2026-03-12T11:46:37.000Z - 3 months ago

Helus Pharma appoints Conwell as Chief People Officer

ACRS

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Mar 12, 2026, 7:30 AM EDT - 3 months ago

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Helus Pharma announces results in Phase 2 signal detection study of HLP004

2026-03-05T13:10:05.000Z - 3 months ago

Helus Pharma announces results in Phase 2 signal detection study of HLP004

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Mar 5, 2026, 7:30 AM EST - 3 months ago

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Cybin Transcript: Study result

Mar 5, 2026, 7:30 AM EST - 3 months ago

Cybin Transcript: Study result

Cybin Press release: Study result

Mar 5, 2026, 7:30 AM EST - 3 months ago

Cybin Press release: Study result

Cybin Slides: Study result

Mar 5, 2026, 7:30 AM EST - 3 months ago

Cybin Slides: Study result

Helus Pharma appoints Freda Lewis-Hall to Board, Chair of Advisory Committee

2026-02-24T13:04:49.000Z - 3 months ago

Helus Pharma appoints Freda Lewis-Hall to Board, Chair of Advisory Committee

PFE

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 24, 2026, 7:45 AM EST - 3 months ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Helus Pharma announces Phase 2a study of SPL026 met primary endpoint

2026-02-17T12:41:20.000Z - 3 months ago

Helus Pharma announces Phase 2a study of SPL026 met primary endpoint

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 17, 2026, 7:30 AM EST - 3 months ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Cybin Earnings release: Q3 2026

Feb 13, 2026, 12:30 PM EST - 4 months ago

Cybin Earnings release: Q3 2026

Helus Pharma reports Q3 net loss $42.7M vs. $7.5M last year

2026-02-13T12:35:56.000Z - 4 months ago

Helus Pharma reports Q3 net loss $42.7M vs. $7.5M last year

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Feb 13, 2026, 7:31 AM EST - 4 months ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 30, 2025, 3:33 PM EST - 5 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Cybin Registration statement: Registration Filing

Dec 19, 2025, 7:00 AM EST - 6 months ago

Cybin Registration statement: Registration Filing

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Dec 18, 2025, 12:29 PM EST - 6 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Cybin Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 7:30 AM EST - 7 months ago

Cybin Transcript: Jefferies London Healthcare Conference 2025

Cybin Earnings Call Transcript: Q2 2026

Nov 13, 2025, 8:00 AM EST - 7 months ago

Cybin Earnings Call Transcript: Q2 2026

Cybin Earnings release: Q2 2026

Nov 13, 2025, 8:00 AM EST - 7 months ago

Cybin Earnings release: Q2 2026

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 13, 2025, 7:20 AM EST - 7 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:30 AM EST - 7 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 4:30 PM EST - 7 months ago

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 6, 2025, 7:30 AM EST - 7 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Cybin Transcript: Future of Health Summit 2025

Nov 5, 2025, 2:00 PM EST - 7 months ago

Cybin Transcript: Future of Health Summit 2025

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 7 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Nov 3, 2025, 7:30 AM EST - 7 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 31, 2025, 4:19 PM EDT - 7 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Cybin Announces $175 Million Registered Direct Offering

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Oct 21, 2025, 8:00 AM EDT - 8 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 23, 2025, 5:00 PM EDT - 9 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 9:20 AM EDT - 9 months ago

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Registration statement: Registration Filing

Sep 17, 2025, 8:00 AM EDT - 9 months ago

Cybin Registration statement: Registration Filing

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 11, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:00 AM EDT - 9 months ago

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 8, 2025, 7:30 AM EDT - 9 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 10:20 AM EDT - 9 months ago

Cybin Transcript: Cantor Global Healthcare Conference 2025

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 9 months ago

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 26, 2025, 7:30 AM EDT - 10 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 10 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Transcript: AGM 2025

Aug 18, 2025, 10:00 AM EDT - 10 months ago

Cybin Transcript: AGM 2025

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 5:30 PM EDT - 10 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Earnings release: Q1 2026

Aug 13, 2025, 4:00 PM EDT - 10 months ago

Cybin Earnings release: Q1 2026

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 2:30 PM EDT - 10 months ago

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Registration statement: Registration Filing

Jul 31, 2025, 8:00 AM EDT - 11 months ago

Cybin Registration statement: Registration Filing

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 11 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 1 year ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Earnings release: Q4 2025

Jul 1, 2025, 12:00 AM EDT - 1 year ago

Cybin Earnings release: Q4 2025

Cybin Annual report: Q4 2025

Jul 1, 2025, 12:00 AM EDT - 1 year ago

Cybin Annual report: Q4 2025

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 1 year ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 1 year ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 1 year ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 1 year ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin Transcript: Fireside Chat

May 29, 2025, 11:00 AM EDT - 1 year ago

Cybin Transcript: Fireside Chat

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 1 year ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

RuddyRolls
RuddyRolls Jun. 8 at 10:31 PM
$HELP cheerful morning here I see
0 · Reply
Alex1710
Alex1710 Jun. 8 at 10:17 PM
$HELP I don't know but it looks like an all time low. Could not get worst. There is defenetly something wrong with this company. Hiring a CEO and making him leave 6 weeks after shows a real management deficiency. CMPS will take the lead, being the first with a new drug gives a major advantage unless your drug is better. Glad I have a small position.
0 · Reply
kev90123
kev90123 Jun. 8 at 8:03 PM
$HELP The "Leadership" team is going on vactions with your money every weekend. Big summer planned!!! @HelusPharmaIR
0 · Reply
matrixtrade123
matrixtrade123 Jun. 8 at 5:56 PM
$ATAI dang Dogs $HELP is making ALL TIME LOWS left that Shit Show years ago when Doug was the Ringleader __ Top Gun Cannabis Stocks finally looking good !
0 · Reply
Buckwacker
Buckwacker Jun. 8 at 5:02 PM
$HELP I’ve averaged down when it fell into the fives, my balls ain’t big enough Man I’m at the point do I sell it take the loss on the chin and try and put the change into quantum or space and rebuild the 💰 Four-five years festering away
0 · Reply
grumpygoose
grumpygoose Jun. 8 at 4:39 PM
$HELP "Sorry kids, there won't be any family vacation this year. Your father invested in HHEELLLPPPPPPPPPP"
1 · Reply
kev90123
kev90123 Jun. 8 at 4:02 PM
$HELP @HelusPharmaIR
0 · Reply
brunoq14
brunoq14 Jun. 8 at 3:43 PM
$HELP Get AI to explain to you what "adjunctive" and "deuteration" mean. Then you'll have a pretty good idea of the advantages of HLP003.
2 · Reply
FruitOs
FruitOs Jun. 8 at 2:26 PM
$HELP we all hate you 😊
0 · Reply
FruitOs
FruitOs Jun. 8 at 2:01 PM
$HELP criminals
0 · Reply
grumpygoose
grumpygoose Jun. 8 at 1:55 PM
$HELP wow red again? Been awhile since we've had a red day....
0 · Reply
kev90123
kev90123 Jun. 8 at 1:50 PM
$HELP @HelusPharmaIR Here it comes! 3!
0 · Reply
leLu83
leLu83 Jun. 8 at 1:47 PM
$HELP i worry spacex will take the last bulls here. How so many have perished over the years... .10 cents pre split now
1 · Reply
everup
everup Jun. 8 at 1:45 PM
$HELP f you go to hell
0 · Reply
kev90123
kev90123 Jun. 8 at 1:40 PM
$HELP Literally any insider but would pop this back up to $5. Why aren't any @HelusPharmaIR insiders buying? Because they know this isn't even a real company. Hello 3's and goodbye 4's FOREVER.
0 · Reply
kev90123
kev90123 Jun. 8 at 12:59 PM
$HELP @HelusPharmaIR
0 · Reply
mcgr
mcgr Jun. 7 at 2:06 AM
$CMPS $ATAI $DFTX $HELP This is your friendly reminder that volatility downward right now is fantastic, and you’ll be purchasing cheaper shares at a more and more derisked stage as we fast approach phase 3 data for the others and NDA for $CMPS . It won’t happen, but I’m PRAYING for a 50% pull back in the sector right into these data drops lol.
3 · Reply
Horseman23
Horseman23 Jun. 6 at 9:57 PM
$ATAI and $HELP need a run
0 · Reply
Buckwacker
Buckwacker Jun. 6 at 9:34 PM
$HELP you look at the website, the pipeline It’s rocking You look at the stock price and the long term bulls here it’s really sad Not just the investment sake but what this drug could do for so many vets… I’m really hoping it all turns out I’ll ride it to zero
0 · Reply
BobbyCucumber
BobbyCucumber Jun. 5 at 9:09 PM
$HELP HELP!
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jun. 5 at 8:57 PM
$CMPS $HELP $ATAI $SPY
1 · Reply